EPO Revokes a Second Ozempic Patent — and the Family Had No Divisional to Fall Back On
EPO Board of Appeal 3.3.04 has revoked Novo Nordisk's EP 3 448 416, reversing its own preliminary opinion. With no divisional pending in the family, there is nothing left to fall back on — and semaglutide exclusivity could now end in 2031…
Read the story →